Tianjin Pharma Invests $20 Million in Neuralstem of the US

Tianjin Pharmaceutical Holding Group has agreed to invest $20 million in Neuralstem, a Maryland company using small molecules and stem cells to treat CNS disorders. Neuralstem plans to use the capital for clinical trials. After the investment, Tianjin will control the equivalent of 40% of Neuralstem's outstanding shares. Neuralstem, which currently has a market capitalization of $38.5 million, is focused on novel CNS treatments. More details.... Stock Symbol: (NSDQ: CUR) Share this with colleagues: // //